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IDENTIFYING HEPATOCELLULAR CARCINOMA (HCC) CELLS 
WITH CANCER STEM CELL-LIKE PROPERTIES 
 
Harshulkumar M. Pandit 
April 17, 2015 
 
Hepatocellular Carcinoma (HCC) is a challenging condition to treat in the 
clinic due to its distinct tumor phenotype, aggressive growth, and chemotherapy 
resistance. Cancer Stem Cells (CSCs) are a poorly differentiated subpopulation 
of cells within the tumor microenvironment, and role of CSCs in tumor initiation 
and chemotherapy resistance is not well understood in HCC. In this study, we 
have successfully identified HCC cells with CSC-like properties that showed 
resistance to Doxorubicin. Using the established serum free culture techniques, 
we have enriched CSC-like cells among hepatocellular cancer cells. These 
enriched cells exhibit all CSC-like properties i.e. self-renewal capability, 
anchorage independent growth with retained proliferation property and resistance 
to Doxorubicin. We confirmed expression of CSC surface markers (EpCAM, 
CD90, CD44, CD133) and functional markers (ALDH activity and dye exclusion 
properties) in enriched HCC-CSCs. Preliminary in vivo data in our  mouse 
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models supports that spheroid forming CSCs show higher rate of tumor 
proliferation compared to untreated (non-spheroid forming) HCC cells. Wnt/β-
catenin pathway components were also found to be overexpressed in CSCs 
when compared to non spheroids. Analysis of 24 paired human specimens from 
HCC tissues by IHC showed higher EpCAM expression, and Western Blot 
analysis suggested concomitant changes in β-catenin and EpCAM levels. In 
conclusion: (1) we have successfully induced and identified HCC cells with CSC-
like properties; (2) Aberrant β-catenin up-regulation mediated Wnt/β-catenin 
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Hepatocellular Carcinoma (HCC):  
HCC, also referred to as hepatoma, is a type of epithelial cancer in liver, 
and most common form of liver cancers in adults, usually age 50 or older. HCC is 
the fifth most common cancer in men and seventh in women worldwide, and 
accounts for the third major cause of cancer related deaths worldwide [1]. HCC 
has different growth patterns, and the most common growth pattern seen in the 
United States is development of HCC secondary to cirrhosis (chronic liver 
damage), where HCC typically starts as several small cancer nodules at multiple 
sites in the liver than just a single large tumor. Men are two to four times more 
likely to develop liver cancer than women. Reports have suggested that 80-90% 
of primary liver cancer incidences in the United States are HCC [1, 2]. A 2013 
CDC report has suggested that liver cancer related deaths in US men is 





Risk Factors, Diagnosis and Treatment Modalities: 
Major known risk factors for HCC are cirrhosis, Hepatitis B virus (HBV) or 
Hepatitis C virus (HCV) infection, alcoholic liver disease, and non-alcoholic fatty 
liver disease (NAFLD) [2]. Newly added risk factors are obesity and type-II 
Diabetes for development of HCC[3, 4]. A recent policy statement by American 
Society of Clinical Oncology (ASCO) reported that obesity will overtake tobacco 
as the leading cause of cancer in near future [5]. In HCC patients, distribution of 
these risk factors are highly variable, depending on ethnic groups and 
geographic regions [6]. Most of these risk factors lead to cirrhosis or its 
progression, which is present in 80-90% of HCC patients. According to a study 
by fattovich et al., the 5 year cumulative risk for HCC development in cirrhosis 
patients ranges between 5% and 30% globally, 18% in the United States, 
depending on cause, ethnic group, and stage of cirrhosis [7]. As a result of the 
variety of causes and risk factors for HCC, patients show vast diversity in clinical 
presentation and disease progression, compared to any other solid malignancies.  
Treatment options following initial diagnosis is based on staging 
guidelines. Standard means of assessing prognosis of HCC patients is Barcelona 
Clinic Liver Cancer (BCLC) staging system and Child-pugh classification system 
[8]. Recommended treatment options for HCC patients are surgical resection of 
tumors, liver transplantation, local ablation, chemotherapy (Doxorubicin), trans-
arterial chemoembolization (TACE) (Doxorubicin), radioembolization, and 
targeted molecular therapy (Sorafenib). Prognosis and disease free survival is 
subjective to individual patient and treatment options. Although, we have gained 
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scientific advances in diagnosis and treatment modalities, HCC is still considered 
difficult to treat because of its late presentation, chemotherapy resistance, and 
high recurrence rate [9]. 
Cancer Stem Cell (CSC) Model and HCC:  
Our view of carcinogenesis and chemoresistance has changed since the 
discovery of Cancer Stem 
Cells (CSC) or Tumor Initiating 
Cells (TIC) [10, 11]. 
Understanding that tumor 
development and growth is not 
only maintained by selection of 
genetically mutated population 
of cells (Stochastic model), but also by the tumor microenvironment which 
facilitates communication between altered tumor cells and their unaltered 
neighbors like fibroblasts, endothelial cells, and inflammatory cells [12]. CSCs 
are a small population of less differentiated cells within the tumor 
microenvironment which possess stem-cell like properties i.e. self-renewal 
capability and ability to differentiate into heterogeneous lineages of cancer cells 
via asymmetric division [10]. CSC model proposes hierarchical organization, 
where apex CSC retains self-renewal capability with highest tumorigenic 
potential (Figure-S2), while bottom most differentiated cancer cells lose this 
important stem-ness property and become less tumorigenic [10, 13]. Lapidot et 




myeloid leukemias (AMLs) in 1994 [14]. A study on breast cancer by Al-Hajj et al. 
was the first to report evidence of CSCs in solid tumor [15]. Since then, several 
studies have been reported presence of CSCs in solid tumors like colon [16], 
pancreas [17], and liver [18-20]. The first direct evidence to support CSC theory 
came from lineage-tracing study by Barker et al. in 2007, where they studied 
tracing of lgr5+ cells in development of small intestine and colon tumors in 
genetically engineered mice [21]. In 2012, two more groups had published 
lineage-tracing studies in genetically engineered mouse models [22, 23].  
Several groups have studied role of CSCs in HCC and reported their 
clinical significance [24, 25]. The CSC tumor model has been proven to show 
clinical relevance in primary HCC and HCC recurrence [25-27]. Haraguchi et al. 
identified a subset of stem cells, “side population” (SP) cells, in Huh-7 and 
Hep3B cell lines which highly express multi-drug resistant ABC-transporters [28]. 
Ma et al. and colleagues have shown that sorted SP cells possess high 
stemness gene expression and higher tumorigenicity [26, 27]. Using 
tumorigenicity potential and stemness characteristics as CSC markers, many 
studies have identified CSCs from human HCC tissues and HCC cell lines 
expressing the following stem cell markers - EpCAM+, CD90+, CD44+, CD133+, 
AFP+, OV6+, and ALDH1+ [25, 27, 29, 30]. These diverse surface markers on 
CSCs have been thought to be a result of  heterogeneity of tumor 
microenvironment, and no single surface marker can define HCC CSCs 
exclusively [31]. In hepatocellular carcinoma, studies have identified EpCAM+ 
cells in tumors of patients, and showed that these EpCAM+ cells correlate with 
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worse prognosis and possess CSC-like properties which showed tumor initiating 
capabilities in as few as 200 cells in a nude mouse model [18, 30, 32-34].  
Recurrence of HCC after definitive tumor treatment occurs in over 70% of 
patients within 14 months of initial treatment. Clinical studies have shown that 
recurrent HCC tumors exhibit resistance to chemotherapy treatments and attain 
aggressive tumor growth [27]. CSCs are resistant to chemotherapeutics and 
considered as the primary players for tumor relapse and metastasis in HCC [35-
37].  Importantly, multi-drug resistant transporter ABCG2, a well characterized 
CSC functional marker, has been implicated for doxorubicin resistance in multiple 
studies [28, 38-41]. Many recurrent HCC cases have a different biology than the 
primary index tumor. These recurrent tumors account for most therapeutic 
failures and eventually result in the death of patients.  Molecular mechanism 
underlying chemotherapy resistance and tumor recurrence in HCC is not yet 
clear.  
Wnt/β-catenin Signaling, CSCs, and HCC: 
Canonical Wnt/β-catenin 
signaling pathway regulates several 
cellular events including cell 
proliferation, and is considered as a 
fundamental pathway in stem cell 
biology [42]. It is one of the most 
extensively studied molecular signaling 
pathways in HCC and CSCs [42]. In the Nature. 2005 Apr 14;434(7035):843‐50.
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absence of Wnt ligand, β-catenin is in a complex with APC, Axin, and GSK-3β 
(termed degradation complex), and gets phosphorylated and targeted for 
ubiquitin mediated degradation. β-catenin also exists in a cadherin-bound form 
and regulates cell–cell adhesion. When Wnt binds to frizzled receptor (Fz) and a 
member of LDL receptor family Lrp5/6 on cell membrane, GSK-3β (non-
phosphorylated, active state) gets phosphorylated at Ser-9 position (inactive 
state). β-catenin is uncoupled and gets stabilized following inactivation of GSK-
3β, and the stabilized β-catenin translocates into the nucleus, where it activates 
target genes by binding to TCF/LET transcription factors. 
Many reports have demonstrated role of Wnt/β-catenin signaling in 
tumorigenic CSCs [42]. EpCAM, one of the important CSC markers, is a target of 
Wnt/β-catenin signaling and inhibiting Wnt/β-catenin signaling has been shown to 
destroy EpCAM-positive cells [34, 36]. Studies have reported role of Wnt/β-
catenin signaling in self-renewal and maintenance of CSCs in HCC [43, 44]. 
Also, ABCG2, a functional CSC marker, was suggested to be regulated by β-
catenin in CSCs and contributes to drug resistance [39, 40, 45].  
Research Direction and Significance of Our Study: 
Published studies have shown increasing evidence that support the role of 
CSCs in HCC carcinogenesis, chemotherapy resistance and tumor recurrence, 
and there is a compelling need to connect and better define these dispersed 
findings. Importantly, well-reported CSC surface marker EpCAM and CSC 
functional marker ABCG2 have been reported as targets of Wnt/β-catenin 
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signaling, and also have been implicated in developing chemotherapy resistance 
and HCC prognosis. However, origin and activation of CSCs in HCC is not 
yet been well defined. Our primary goal is to understand the role of Wnt/β-
catenin pathway in HCC CSC activation and development of chemotherapy 
resistance. In pursuit of this goal, our first task was to enrich, identify and 
characterize CSCs in our laboratory setting.  
In the present thesis work, we have successfully identified HCC cells with 
CSC-like properties in hepatoma cell lines using in vitro spheroid culture. These 
CSCs are poorly differentiated, and possess all defined CSC properties i.e. self-
renewal, proliferation, and chemotherapy resistance. Surface markers analysis 
(EpCAM, CD90, CD44, and CD133) and functional markers analysis (ALDH and 
Hoechst efflux assays) further confirmed enrichment of CSCs, especially 
EpCAM+ CSC cells. Preliminary in vivo data in the mouse models support that 
spheroid forming CSCs show significant higher tumor proliferation rate compared 
to untreated (non-spheroid forming) HCC cells. Analyzing Wnt/β-catenin pathway 
components in CSCs showed up-regulation of β-catenin expression, which is 
most likely a result of changes in GSK-3β phosphorylation.  Analysis of 24 paired 
human HCC specimens showed higher EpCAM expression compared to 












MATERIALS AND METHODS 
 
Cell Lines and Animal Models:  
We have primarily used a mouse hepatoma cell line Hepa1-6 (ATCC CRL-
1830) for all in vitro experiments. Hepa1-6 cell line is derivative of the BW7756 
mouse hepatoma that arose in a C57L mouse. Hepa1-6 cells bear tumor 
initiating capabilities in an immune competent C57LJ mouse, in orthotopic as well 
as hind limb models. Use of Hepa1-6 cells with C57LJ mouse equipped us to 
establish the best HCC orthotopic model possible resembling clinical HCC 
closely in our lab.  
We confirmed our findings in human hepatoma cell lines, Hep3B (ATCC 
HB-8064) and HepG2 (ATCC HB-8065). Our lab has an established HCC 
orthotopic animal model using Hep3B cells in BLAB/C nude mice.  
Cell Culture and Spheroid Formation:    
Hepa1-6 and Hep3B cells were grown in DMEM (MediaTech, Corning, Cat 
#  10-013-CV) with 4.5% Glucose, supplemented with 10% FBS (Sigma, Cat # 
F2442), 100 IU/mL Penicillin, 100 µg/mL Streptomycin, 0.25 µg/mL  Amphotericin 
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(Antibiotic and Antimycotic, MediaTech Corning, Cat # 30-004-CI), 10 µg/mL 
Tylosin (Antimycotic, Sigma, Cat # T3397).  HepG2 cells were grown in Minimum 
Essential Media (MEM, Gibco, Cat # 11095-080), supplemented with 10% FBS 
(Sigma, Cat # F2442), Non Essential Amino Acids (Gibco, Cat # 11140-050), 
Sodium Pyruvate (Gibco, Cat # 11360-070), 100 IU/mL Penicillin, 100 ug/mL 
Streptomycin, 0.25 µg/mL  Amphotericin (Antibiotic and Antimycotic, MediaTech 
Corning, Cat # 30-004-CI), 10 µg/mL Tylosin (Antimycotic, Sigma, Cat # T3397).   
For in vitro enrichment of Cancer Stem Cells (CSCs), we employed a 
widely used and accepted spheroid formation assay. Hepa1-6, HepG2, and 
Hep3B cells were grown in a serum-free condition (SF Group) in DMEM/F12 
(1:1) media (SIGMA, Cat # D6434), supplemented with 2 mM L-Glutamine 
(SIGMA, Cat # G7513), 20 ng/mL recombinant human Epidermal Growth Factor 
(EGF, Sigma, Cat # E9644 ), and 10 ng/mL recombinant human basic Fibroblast 
Growth Factor (bFGF, Sigma, Cat # F0291 ), 100 IU/mL Penicillin, 100 ug/mL 
Streptomycin, 0.25 µg/mL  Amphotericin (Antibiotic and Antimycotic, MediaTech 
Corning, Cat # 30-004-CI), 10 µg/mL Tylosin (Antimycotic, Sigma, Cat # T3397).  
Self-Renewal Assay: 
Hepa1-6 cells were seeded in serum-free (SF) media at a density of 2000 
cells/well in 6-well plate, and incubated for 4 days to allow the development of 
speroids. After confirming formation of spheroids under the microscope, these 
spheroid population of cells were collected in 15 mL centrifuge tube, treated with 
trypsin-EDTA for 4 minutes, and prepared single-cell suspension with 500 
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cells/mL density with SF media. Seed single cell suspension at 2 uL/well in 96 
well plate. Mark the wells with one or two cells. Add 150 uL SF media in each 
marked well and monitor for 20 days. Images were taken on a daily basis to track 
progress.  
Cell Proliferation Assay: 
Cell proliferation was measured using the MTT assay (3-(4,5-dimthyl-
thiazol-2-yl)-2,5 diphenyltetrazolium bromide) in a 96 well format. Hepa1-6 cells 
were seeded in triplicates at a density of 3000 cells/well in complete media 
(control group) or serum-free media (SF group) and grown overnight. A separate 
plate was prepared for each time-point (0, 24, 48, 72, and 96 hours). After 
appropriate incubation period, MTT was added in each well at the final 
concentration of 0.5 mg/mL, and plate was incubated for 3 hours at 37 °C in CO2 
incubator. After MTT incubation, media was removed from each well and 100 uL 
DMSO was added to dissolve formazon crystals which generate violet color. 
Absorbance was measured with plate reader at 540 nm with appropriate controls 
in each plate. For purpose of calculation, we considered the shorter incubation 
time MTT reading (overnight) as 0 hour and set it as control for the subsequent 
time points.    
Doxorubicin (Adriamycin) Resistance Assay:  
Hepatoma cells (Hepa1-6, HepG2, and Hep3B) were seeded at a density 
of 5000 cells/well in a 96 well plate in triplicates, with one set of control group 
(complete media) and two sets of spheroids group (serum-free media). Separate 
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96 well plates were seeded for different time points (24, 48, 72 and 96 hours) 
simultaneously on the day of seeding. After 24 hours, serum-free media is 
replaced with complete media in one of the two sets of spheroids group (termed 
as SFR, reserum) and incubated for another 24 hours. On the day 3, media is 
replaced with complete or serum-free media containing different concentrations 
of Doxorubicin (0.05 µM, 0.5 µM (clinical), and 5 µM (10x clinical)) (SIGMA, Cat # 
D1515). MTT assay was performed at 24, 48, 72, and 96 hours after initiating 
DOX treatments as described in the cell proliferation assay.  Each plate and 
group had appropriate untreated control in triplicates, and corresponding data for 
untreated group was considered as 1 i.e. 100 % viability. DOX treated cells were 
normalized to their corresponding untreated controls on the same plate, 
compared and analyzed.   
Flow-Cytometry Analysis:  
Hepa1-6 control or 7 day spheroid cells grown in 100 mm discs were 
collected by gentle cell scraping. Collected cells were passed through 50 micron 
strainer 5 times to remove cell clumps, followed by repeate pipetting for 10-20 
times to obtain closest single cell suspension. Use of trypsin was avoided to 
preserve integrity of surface receptors to its best. Cell numbers were counted 
and single cell suspension was verified using a Hemocytometer.  Each sample 
was transferred to a 15 mL tube and centrifuged for 5 minutes at 300 RCF to 
obtain cell pellet. Cell pellets were washed 2 times with 2% BSA/PBS. Pellets 
were resuspended in 100 uL 2% BSA/PBS and transferred into 1.5 mL microfuge 
tubes. Corresponding unstained and single stained controls were seperated for 
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each sample, 106 cells/100 uL. FITC, APC or PE conjugated primary antibodies 
were added in 100 uL of cell suspension as per datasheet or in-house optimized 
dilution (1:100 for most experiments and antibodies).  Samples are gently 
vortexed and incuabted in the dark at 4 °C for 1 hour. After incubation, cells were 
washed once with 1 mL 2%BSA/PBS, resuspended in 500 uL 2% BSA/PBS, 
transferred into labeled flow-tubes, and stored in the dark on ice until analysis 
were performed. Data were recorded on BD FACSCanto. For analysis, after 
correct set-up of voltages for FSC and SSC, live cells were gated to exclude 
dead cells and cell debris.  Required compensations were performed for dual 
FITC and PE staining experiments. In majority of our experiments, we chose 
FITC and APC (emission spectra don’t overlap). Data analysis was performed 
either by FACS Diva or FlowJo software suites. 
Immunocytochemistry (ICC) Staining:  
 Hepa1-6 control or spheroid cells were grown in 8 well Nunc™ Lab-Tek-II 
chamber slide (Thermo scientific, Cat # 154534) for 7 days (seeded at 100 
cells/well to avoid overgrowth at the end of 7 days). Media was changed on the 
4th day to ensure viability.  Cells were fixed with 4% PFA for 30 minutes (or 70% 
ethanol overnight). Fixed cells were washed 2 times for 15 minutes with PBS-T,  
and blocked with 10% BSA in PBS for 20 minutes. Blocked cells were washed 
again for 2 times for 15 minutes with PBS-T and incubated with 100 uL primary 
FITC conjugated antibodies at room temprature for 2 hours (EpCAM, CD90, 
CD133, 1:100 dilution in 10% FBS in PBS-T). Following antibody incubation, 
cells were given 3 time 10 minute PBS-T washes and stained for nuclear staining 
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with DAPI (1:1000 dilution).  After DAPI staining, cells were given 2 time 10 
minute PBS-T washes. Plastic chambers were removed from each Lab-Tek 
slides as per manufacterur’s instructions, using the tools provided and exposed 
glassslide surface with cells were sealed with coverslip using 5-10% glycerin. 
The slides were examined using  Olympus 1×51 microscope at 20x magnification 
using the Olympus DP72 digital camera via the cellSens Dimention imaging 
system (Olympus, Pittsburgh, PA) with FITC, DAPI and brightfield settings. 
Digital images were taken, stored and then overlapped using software tool to 
analyzed for FITC positive cells in each experiments.  
Aldefluor Assay for ALDH Activity: 
Aldefluor activity was assayed in Hepa1-6 control and spheroid cells using 
Aldefluor kit according to the manufacturer’s instructions (Stemcell technologies, 
Canada). Briefly, 3 mL of cell suspension was prepared in DMEM without serum 
at 106 cells/mL final dilution. These cells were centrifuged at 250 RCF for 5 
minutes, and pelleted cells were resuspended in 3 mL of Aldefluor buffer on ice. 
To get the fluorescence product, we added 45 uL of Aldefluore substrate into 3 
mL of the each of the cell suspension samples on ice. Immediately after mixing, 1 
mL was transferred into a new tube containing 30 uL ALDH1 inhibitor 
diethylaminobenzaldehyde (DEAB), and later used as an inhibitor control 
(negative control). Test samples and negative controls were incubated at 37 °C 
for 45 minutes, mixed every 10 minutes. Then, cells were cenrifuged at 250 RCF 
for 5 minutes, resuspended in Aldefluore buffer and incubated on ice for 1 hour. 
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Data were recorded on BD FACSCanto at FITC channel with 488 excitation 
laser. 
Hoechst 33342 Efflux Assay: 
 After 7 days in culture, Hepa1-6 Control or spheroid cells were harvested 
in 15 mL centrifuge tubes. 5 mL cell suspension with 106 cells/mL was prepared 
for each sample, centrifuged at 250 RCF for 5 minutes, washed two times and 
resuspended in 2%FBS in PBS. Hoechst 33342 (Life technologeis, Cat # H1399) 
dye was added to 5 mg/mL final concentration in 2% FBS in PBS and cells were 
incubated for 90 minutes at 37 °C. Cells were then incubated on ice for 10 
minutes, and followed by a single wash of ice cold 1X PBS. These cells were 
immediately mounted on glass slides and analyzed within 1 hour on a 
fluorescence microscope with UV excitation settings. It is imperative that cells 
were viable during the steps of the assay. Hoechst 33342 dye stains the nuclear 
compartment  and is visible at 355 nm excitation (blue color) using the common 
DAPI filter. Cells with dye exclusion property were identified by 
comparing/overlaping with images obtained under brightfield settings.  
Protein Extraction and Western Blot:   
After treating cells with respective media and/or regulators for desired 
time, media was aspirated from the culture and cells were washed two times with 
1X PBS. Cells were lysed by adding SDS lysis buffer (supplemented with 
protease and phophatase inhibitors, Thermo scientific, Cat # 78443) directly into 
wells (100 uL per well of 6-well plate or 500 uL per 100 mm plate). For spheroids 
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group (non-adharent cells), cells were collected by gentle scraping and pipetted 
into 15 mL centrifuge tube. Culture media was removed by centrifugation for 5 
mins at 150 RCF to collect cells followed by two time 1x PBS washes to remove 
all media traces. Lysis buffer was then added into the tube according to pelleted 
packed cell volume (100 uL lysis buffer for each 20 uL packed cell volume). Cells 
were transfered to 1.5 mL microfuge tube and sonicated for 10-15 seconds on 
ice. After 30 minutes incubation on ice, lysates were centrifuged for 30 minutes at 
14,000 RCF at 4 °C. Supernatant containing total cellular protein was collected 
carefully and transfered to new labeled 1.5 mL microfuge tube.  Purified protein 
samples were stored at -80 °C untill further use. For cytoplasmic and nuclear 
fractionation, we used a commercially available kit (Pierce, ThermoFisher, Cat # 
78833). Fractionation was performed as per manufacturer’s protocol. Extracted 
protein were stored at -80 °C untill further use. 
Extracted protein was quantified using the Bradford assay (Biorad, Cat # 
500-0006) in a 96 well plate format and readings were performed at 620 nm 
using the ELISA reader (MultiSKAN MCC/340, Thermo Scientific).  
Equal protein (20-50 µg each) were loaded for SDS-PAGE electrophoresis 
on 8% gel. Protein samples were seperated by SDS-PAGE  and then 
electrotransferred onto nitrocellulose membrane (Amersham, GE) . Following 
electrotransfer, the membane was blocked in 5% non-fat milk for 1 hour at room 
temprature. The membrane were incubated in primary antibody overnight at their 
best working concentration (1:1000 or 1:2000 final dilution). Next day, the 
membrane with overnight incubated primary antibodies were washed 3 times 
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with TBST for 7 minutes each. Next, the membrane was incubated for 1 hour in 
secondary HRP conjugated-Anti-Mouse IgG (Cell Signaling, Cat # 7076; OR 
Santacruz Biotech, Cat # sc-2005) or secondary HRP conjugated-Anti-Rabbit 
IgG (Call Signaling, Cat # 7074; OR Santacruz Biotech, Cat # sc-2004 ). 
Secondary antibodies were diluted either 1:2000 or 1:4000 as per experimental 
requirement. Secondary antibody blot was washed 3 times by TBST, followed by 
1 wash of TBS and incubated in dark for 1 minute in Westen Blot Luminol 
Reagent (Santacruz Biotech, Cat # sc-2048).  Chemiluminescence signals were 
detected in the darkroom using x-ray films. Densitometry analysis were 
conducted using ImageJ software (NIH).  
Primary antibodies:  β-Catenin (SantaCruz Biotech, Cat # sc-7963), β-
actin (SantaCruz Biotech, Cat # sc-81178) , GAPDH (SantaCruz Biotech, Cat # 
sc-365062), GSK3β (Cell Signaling, Cat # 9832), phospho-GSK3β (Ser-9) (Cell 
Signaling, Cat # 5558), ABCG2 (Cell Signaling, Cat # 4477), Cyclin-D1 (Cell 
Signalling, Cat # 2978), TCF-1 (Cell Signaling, Cat # 2203), C-MYC (Cell 
Signaling, Cat # 5605). 
Animal Experiments:  
All experimental procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC) at University of Louisville (UofL). IACUC at 
UofL is certified by American Association for Accreditation of Laboratory Animal 
Care. All mice were housed in the University of Louisville Research Resources 
Center at 22 °C with 12-h light/dark cycle with free access to food and water.  
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In vivo experiments using Hepa1-6 cell-lines were performed in 8 week old 
C57L/J mice (All male).  Each group had 3 animals. For orthotopic inoculation, 
1x107 Hepa1-6 control or spheroid forming cells (serum free group – 7 day 
treatment), were injected into liver of the animal. Post injection, mice were 
monitored for two weeks and then euthanized. Animal weight, liver weight, tumor 
weight, and tumor size were recorded for each animal. In vivo study using human 
Hep3B cells was performed in the same way in 8 week old orthotopic BLAB/C 
nude mouse model. 
Human HCC Specimens: 
This study was approved by the Institutional Review Board for Human 
Study at University of Louisville. The study samples were retrospectively 
collected from 24 patients who had undergone liver resection for hepatocellular 
carcinoma between 2002 and 2013. 24 subjects, 13 male (54.2%) and 11 female 
(45.8%) with a median age of 67, ranging from 41 to 84 years old, had a clinical 
diagnosis of hepatocellular carcinoma and underwent liver resection.The control 
samples consisted of the same 24 patients’ normal adjacent tissue that were 
within the resected liver specimen.   
Immunohistochemical Assay for EpCAM in Human Specimens: 
EpCAM protein expression were determined by using an 
immunohistochemical assay. Staining was carried out on the paraffin-embedded 
tissues using the DAKO EnVisionTM+System kit (DAKO Corporation, 
Carpinteria, CA) according to the manufacturer’s instructions. The sections were 
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deparaffinized and hydrated, then the slides were washed with TRIS buffer.  
Peroxidase blocking was performed for 5 minutes. After rewashing, the slides 
were incubated with EpCAM antibody (1:100) (SantaCruz Biotechnology Inc, CA) 
for 30 minutes at room temperature.  The slides were rinsed and the specimens 
were incubated with the labeled polymer for 30 minutes at room temperature.  
Then, the chromogenic substrate diaminobenzidine was added as a visualization 
reagent.  Finally, the slides were counterstained with methyl green for EpCAM.  A 
negative control was included in each run. 
Computer Image Analysis of IHC:  
A computer image analysis was performed to quantify the expression of 
EpCAM in the 24 samples diagnosed with HCC, and in the 24 samples of 
adjacent normal liver (AD).  The imaging fields were chosen randomly from 
various section levels to ensure objectivity of sampling. Five imaging fields were 
scanned for each specimen sample.  All digital images were acquired with the 
Olympus i×51 microscope at 40x magnification using the Olympus DP72 digital 
camera via the cellSens Dimention imaging system (Olympus, Pittsburgh, PA) 
and stored as JPG data files with fixed resolutions of 200 pixels/inch.  The 
acquired color images from the immunohistochemical staining were defined at a 
standard threshold according to the software specification.  The computer 
program then quantified the threshold area represented by color images.  
EpCAM protein expression was defined by the percentages of threshold area in 
acquired color images. 
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Statistical Analysis:  
Data are presented as mean ± S.D. (n ≥ 3 per group). Comparisons were 
performed by two-tail student’s t-test with equal variance (Microsoft Excel 2013). 
For analysis of human specimens, analysis of variance (ANOVA) was used to 
determine the differences in EpCAM expression between paired samples. 











Hepatoma Cells Could Form Anchorage-Independent, Self-Renewing 
Spheroids (Spheres) in Serum-Free Culture in vitro: 
Serum-free conditions enriched in growth factors allow cells to grow in 
anchorage-independent manner, and is a well-documented and standard method 
for maintaining undifferentiated cells [46]. This technique is widely adapted for 
CSC studies in breast cancer [47] and glioblastoma [48]. Soon after, this 
technique was accepted and used in many other solid tumor malignancies 
including hepatocellular carcinoma [27, 49].  Also known as spheroid formation 
(sphere formation) culture, this is not only a CSC property, but also serves as a 
valuable tool to enrich CSC-like cells in vitro.  
To enrich HCC CSCs from hepatoma cell lines in vitro, we employed 
serum-free conditions using DMEM/F-12 (1:1) media supplemented with 
recombinant human Epidermal Growth Factor (EGF) and basic Fibroblast Growth 
Factor (bFGF). We evaluated spheroids for CSC properties. We found that all 
three hepatoma cell lines (Hepa1-6, HepG2, Hep3B) successfully formed 
spheroids in serum-free conditions (Figure-1).  
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Self-renewal capability is the most fundamental property of CSCs and 
proposed as the primary mechanism responsible for maintaining undifferentiated 
cells with CSC like properties in tumors [50]. We have primarily characterized 
Hepa1-6 spheroids.  To test if enriched Hepa1-6 spheroids possess self-renewal 
capability, we performed two separate experiments. In the first experiment, we 
tested if spheroid cells can be serially passed from one generation to the next 
without dying or losing spheroid forming capability.  The rationale behind this 
experiment is that well differentiated cells cannot survive in serum-free stress 
conditions optimized for anchorage independent growth, while only cells with 
stem-like properties are able to maintain themselves and propagate. Hepa1-6 
spheroids were serially passaged for more than 10 generations in serum-free 
conditions, indicating their self-renewal capability (data not shown).  
In the second experiment, we confirmed self-renewal capability of CSC 
like cells by means of more quantitative “self-renewal assay”.  Hepa1-6 spheroid 
cells were seeded in 96 well plates (single cell/well) and monitored for their 
growth pattern daily for 20 days (Figure-2). In this condition, cells can have one 
of the three fates: 1) self-renewal (spheroid formation), 2) differentiation 
(adherent phenotype), 3) quiescence (stays as a single cell). Approximately, 24% 
Hepa1-6 cells showed self-renewal capability by forming spheroids. These 
growing spheroids (Figure-2.A & C) also expressed EpCAM (CSC marker), 
further supporting CSC like-properties of spheroids.  Around 51% cells stayed in 
the quiescence state, while about 25% cells lost their stem-ness and proceeded 
to differentiation (Figure-2.D).   
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We also performed an MTT assay to quantitate cell proliferation rates in 
Hepa1-6 control and spheroid cells.  We have found that Hepa1-6 spheroids 
retained proliferative capability but growth rate is significantly slower than 





















Figure 1.  Representative Images of Cultured Cells. Bright field microscope 
images. (A) Control hepatoma cells and (B) CSC Spheroids (Serum-free /SF 
group) in Hepa1-6, HepG2, and Hep3B cell lines.  4x (Bar = 500 µm), 10x (Bar = 































































































































































































































































































Figure 3.  Hepa1-6 Spheroids Retained Proliferative Capability. MTT Assay was 
performed in 96 well plate, with seeding 3000 cells/well in triplicates.  CSC spheroids 
retained proliferative capabilities in serum-free media, but exhibit slower growth rate 
compared to control group cells (complete media with serum).  n= 3 independent 
experiments. Values shown in “Mean ± S.D”. 
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HCC Spheroids Possessed Resistance Ability to Chemotherapy Drug 
Doxorubicin: 
Resistance to chemotherapeutics is another important characteristic of 
CSCs, and is believed to play a significant role in HCC carcinogenesis and 
recurrence [24]. Currently, doxorubicin (Adriamycin, DOX) is a first line drug used 
for HCC treatment in clinics [2].  
We studied Hepa1-6 spheroids for their DOX resistance property with 
MTT assay as described in materials and methods.  For in vitro experiments, we 
selected a clinical relevant dose (0.5 µM) as characterized in early 
pharmacokinetic studies in patients and widely employed by other groups for 
DOX studies [51].  We have also tested 1/10 (0.1x, 0.05 µM) and 10 times (10x, 
5 µM) doses for characterization. Time dependent dose response curves have 
demonstrated that Hepa1-6 CSC spheroids were sensitive to DOX at early time 
points, but developed resistance 48 hours post DOX treatment at both subclinical 
and clinical doses (Figure-4). We found that for the 10x dose, 5 µM, there were a 
fraction of cells that retained higher viability after 72 hours.  
When we further analyzed our data by plotting log (DOX dose) v/s viability 
at 96 hour time-point, we found that Hepa1-6 spheroids required 2 times more 
DOX compared to control cells to eradicate 50% viable cells (Figure-5.A).  
Hepa1-6 spheroids were seen to have significantly increased chemotherapy 
resistance for doxorubicin at not only physiologically relevant dose of 0.5 µM but 
also to 10 fold dose increase (5 µM) (p<0.005) (Figure-5.B). 
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We have also investigated HepG2 and Hep3B spheroids for their DOX 
resistance properties. After 96 hours of treatment, both HepG2 and Hep3B CSC 
spheroids showed significant higher resistance for DOX compared to control cells 
at clinical dose of 0.5 µM (p<0.05) (Figure-6). These data support our results 










































































































































































































































































































































































































Control 0.05 µM 0.5 µM 5 µM
C 1.00 ± 0.0 0.61 ± 0.02 0.27 ± 0.04 0.03 ± 0.01
SF 1.00 ± 0.0 0.66 ± 0.04 0.45 ± 0.07 0.09 ± 0.03
SFR 1.00 ± 0.0 0.57 ± 0.09 0.32 ± 0.06 0.03 ± 0.02
Doxorubicin (ADR) Resistance ‐ MTT Assay  ( Hepa1‐6 Cells)
Doxorubicin Treated (Concentrations) 
A
Figure 5.  Hepa1-6 Spheroids Exhibit Doxorubicin Resistance. Value 1 on y-axis 
represents 100% cell viability. (A) Dose dependent response curve (Log [Dox] v/s Cell 
viability) after 96 hours of Doxorubicin treatment. Hepa1-6 spheroids required increased 
Doxorubicin dose (2 times higher than C, and 4 times higher than SFR) to eradicate 50% 
cells.  (B) Hepa1-6 spheroids (SF) are more resistant to Doxorubicin compared to control(C). 
n=3 independent experiments, values shown in “Mean ± S.D”, *(p<0.05), NS=No 






Figure 6.  Human HepG2 and Hep3B Spheroids Showed Doxorubicin Resistance 
Property, Supporting Findings in Mouse Hepa1-6 Cells. HepG2 or Hep3B cells were 
seeded in 96 well plate in triplicates at 3000 cells/well and studied for their chemotherapy 
resistance properties by MTT assay. Value 1 on y-axis represents 100% cell viability. (A) 
Doxorubicin resistance in HepG2 cells. (B) Doxorubicin resistance in Hep3B cells. For 
both human cell lines, HepG2 and Hep3B, spheroids showed higher resistance to 
Doxorubicin compared to corresponding controls. Values have shown in “Mean ± S.D”,  
*(p<0.05), NS=No significance (p>0.05). C= Control group, SF= Serum-free group, SFR= 
Reserum group.    
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Enriched HCC Spheroids Showed Higher Expressions of Cancer Stem Cells 
(CSCs) Surface Markers and Functional Markers: 
Surface and functional markers are currently the best available tools to 
define the origin and lineage of cells in animal tissues, and therefore, these tools 
are extensively employed to characterize CSCs in solid malignancies including 
HCC [11, 31, 52].  Most extensively characterized and reported surface markers 
for HCC CSCs are EpCAM, CD90, CD44, AFP, OV6, and CD133 [27, 31, 53].  It 
is noteworthy that EpCAM+ and CD90+ cells are physiologically different in terms 
of their tumorigenic potential and differentiation stage [34], and so is true for 
other markers. Because of a high degree of heterogeneity, no single maker could 
confidently and exclusively define HCC CSCs. Extensive research is being done 
globally in this pursuit. 
In order to confirm CSC-like properties in HCC spheroids, we selected 
extensively reported and studied surface markers i.e. EpCAM, CD90, CD44, and 
CD133, and tested HCC spheroids for their expression by flow-cytometry and 
ICC.  Our findings suggest that HCC spheroids showed up-regulation in EpCAM 
levels compared to control, and EpCAM+ cells are enriched in spheroid culture 
(Figure-7.A). We confirmed our findings with ICC using anti-EpCAM antibodies 
(Figure-7.B).  We have also confirmed up-regulation of CD90, CD44, and CD133 
in spheroid culture with enrichment of CD90+, CD44+, CD90+/CD44+, and 
CD133+ cells (Figure-8).  Each of this subpopulations bears different 
physiological properties and differentiation states e.g. CD44+/CD90+ cells were 
suggested as more tumorigenic and less differentiated compared to 
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CD44+/CD90- or CD44-/CD90+ cells alone [31].  Our findings confirmed that in 
vitro Hepa1-6 spheroids can enrich all important CSC subpopulations reported so 
far. 
As it is defined by its asymmetric cell division property and hierarchical 
importance, the CSC theory is a functional concept. Two extensively reported 
functional markers to define CSCs, ALDH activity and Hoechst 33342 efflux 
assays [28, 54], were also tested in Hepa1-6 CSC spheroids. Hepa1-6 spheroids 
showed 1.3% increase in ALDH+ cells (Figure-9.A). Also spheroid cells have 
showed property of dye exclusion (Figue-9.B), which was confirmed by Western 
Blot analysis of ABCG2, multi-drug resistant transporter responsible for dye 
exclusion (Figure-9.C). Dye efflux depends on expression and activity of ABCG2, 







Figure 7.  Hepa1-6 Spheroids Showed Increased EpCAM Expression. Hepa1-6 cells 
were grown in serum-free media (spheroids) or control media for 7 days. After 7 day 
treatment, cells were harvested and analyzed for EpCAM expression. (A) EpCAM 
expression analysis by flow-cytometry using APC conjugated Anti-EpCAM antibodies, 
**(p<0.005), n=4 independent experiments, (B) EpCAM expression analysis by ICC using 
FITC conjugated Anti-EpCAM antibodies. 7 Day SF treatment. Cells were fixed, stained 
and analyzed by fluorescence microscopy at 20x magnification (Bar = 100 µm). DAPI 







Figure 8.  Hepa1-6 Spheroids also Showed Increased CD44, CD90 and CD133 
Expression, Well Reported CSC Surface Markers. Hepa1-6 cells were grown in 
serum-free media (spheroids) or control media for 7 days. After 7 day treatment, cells 
were harvested and analyzed for corresponding markers. (A) CD44 and CD90 
expression analysis by flow-cytometry, and CD90 analysis by ICC. (B) CD133 
expression analysis by flow-cytometry and ICC. Cells were fixed, stained and analyzed 
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Figure 9.  Hepa1-6 Spheroids Showed Increased CSC Functional Markers. 
Hepa1-6 cells were grown in serum-free media (spheroids) or control media for 7 days. 
After 7 day treatment, cells were harvested and analyzed. (A) Aldefluore assay 
showing higher ALDH enzyme activity in CSC spheroids compared to control. (B) 
Hoechst 33342 efflux assay - ICC representative images of spheroids showing dye 
efflux, contributed by ABCG2 activity. Stem-like cells with high ABCG2 activity show 
less staining compared to normal cells (low ABCG2 activity). ICC at 10x magnification 
(Bar = 200 µm). Hoechst 33342 stains nuclei. (C) Representative Western Blot and 
densitometry analysis of ABCG2 expression. Increased ABCG2 expression in 







Up-Regulation of β-catenin in HCC CSC Spheroids:  
Many signaling pathways are implicated and studied in CSCs [55]. Wnt/β-
catenin pathway is the cardinal pathway in normal stem cell maintenance and 
highly implicated in HCC and CSCs [42, 56].  
Enriched Hepa1-6 CSCs showed increased β-catenin protein levels both 
in the cytoplasm (1.53 ± 0.21 fold, P<0.05) as well as in nucleus (1.54 ± 0.15 
fold, p<0.001) compared to control cells (Figure-10). We have also tested β-
catenin levels in HepG2 cells and found it to be consistent with our findings in 
Hepa1-6 cells (data not shown, downstream target studies were not completed in 
HepG2 cells when this thesis was being written).  
To further confirm functional consequences of higher β-catenin levels in 
Hepa1-6 CSC spheroids, β-catenin downstream targets (C-MYC, Cyclin-D1, 
LEF1) were analyzed by Western Blot analysis. All three downstream targets we 
tested were proportionately increased with increased β-catenin levels (Figure-
11), suggesting that higher β-catenin levels in CSC spheroids have functional 
consequences. More importantly, C-MYC and Cyclin-D1 are highly implicated in 
carcinogenesis [12].  
To further investigate the increase in β-catenin levels, we tested GSK-3β 
phosphorylation status. Active GSK-3β (no Ser9 phophorylation) directs 
cytoplasmic β-catenin to ubiquitin mediated proteaosomal degradation by 
phophorylating β-catenin at S33/S37/T41 positions. However, when GSK-3β 
itself is phosphorylated at Ser9 position, it loses its substrate specificity for β-
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catenin and cytoplasmic β-catenin gets stabilized, translocates to the nucleus 
and regulates transcription at the gene level. Hepa1-6 CSC spheroids showed 
increase in inactive GSK-3β levels (phosphorylated at Ser9) compared to control 
cells (Figure-12). This finding suggests that GSK-3β activity at least partially 
contributed to increased β-catenin levels in Hepa1-6 spheroids and needs to be 























Figure 10.  Hepa1-6 Spheroids Showed Increased β-catenin Levels. Hepa1-6 cells 
were grown for 7 days in serum-free media (SF) or complete media (control). Cells were 
harvested after 7 day treatment, and cytoplasmic and nuclear proteins were extracted.  (A) 
Representative Western Blot. (B) Densitometry image analysis. * (p≤0.05), **(p≤0.005), 
n=3 independent experiments. β-actin used as loading control. Cyto = Cytoplasm; Nuc = 






Figure 11. Hepa1-6 Spheroids Showed Increased Expression of β-catenin 
Downstream Targets. Hepa1-6 cells were grown for 7 days in serum-free media (SF) or 
complete media (control). Cells were harvested after 7 day treatment, and total proteins 
were extracted using SDS buffer. All three β-catenin downstream targets i.e. TCF-1, C-
MYC, and Cyclin-D1, were found to be increased in CSC spheroids compared to control. 
(A) Representative Western Blot, (B) Densitometry image analysis. β-actin used as 







Figure 12.  Higher β-catenin Levels in Hepa1-6 Spheroids May Be Contributed Via 
GSK-3β Activity. Hepa1-6 cells were grown for 7 days in serum-free media (SF) or 
complete media (control). Cells were harvested after 7 day treatment, and total proteins 
were extracted using SDS buffer. No change was observed in total GSK-3β levels, but 
phosphorylated GSK-3β (Ser9) levels were increased in CSC spheroids compared to 
control. (A) Representative Western Blot, (B) Densitometry image analysis. **(p≤0.005), 
n=3 independent experiments. β-actin used as loading control. C=Control; SF=Serum-free. 
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HCC CSC Spheroids Possess Higher Tumorigenic Capability in vivo:  
CSCs have been suggested to possess increased tumorigenic properties 
in vivo. To test tumorigenic potential of Hepa1-6 spheroids, we used an 
orthotopic C57LJ mouse model. We injected seven days cultured 1X107 Hepa1-6 
spheroids and non-spheroid control cells into livers of 8 week old 
immunocompetent C57LJ mice (n=3 mice in each group) and monitored for two 
weeks.  Mice injected with Hepa1-6 spheroids developed more aggressive 
tumors with overall higher tumor volume (5800 mm3) compared to mice injected 
with non-spheroid cells (1900 mm3) (Figure-13.A). Aggressive nature of CSC 
tumors was also witnessed at multiple sites within the liver compared to control, 
suggesting that CSC spheroids possess increased tumor initiation capabilities 
(Figure-13.A). Increased liver weight was observed in spheroid group (3.9 ± 1.6) 
compared to control group (1.7 ± 0.43), which is likely due to aggressive growth 
and higher tumor mass in spheroids injected group. This justifies the increased 
overall body weight by about 2.3 gms in spheroids group compared to control.   
We were unable to perform statistical tests for significance because one Hepa1-6 
spheroids injected mouse died within 2 weeks of injection due to extremely 
aggressive tumor growth. 
 We also studied Hep3B spheroids in orthotopic BALB/C nude mouse 
model. Hep3B spheroids also supported our findings in Hepa1-6 and showed 
aggressive tumor growths in the spheroid group compared to non-spheroid group 
(Figure-13.B). EpCAM is extensively reported CSC marker in HCC, and also 
found to be higher in our Hepa1-6 spheroids.  We studied EpCAM expression by 
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Western Blot in Hep3B xenograft tissues, and found EpCAM up-regulation in the 





Figure 13.  CSC Spheroids Possessed Higher Tumorigenic Capability. Tumors in 
spheroid group animals were more aggressive and proliferative compared to control. (A) 
Upper-Orthotopic C57LJ mice with 1x107 CSC spheroids or control Hepa1-6 cells injected 
into liver of each animal (n=3 animals in each group). Lower- quantified tumor volumes. 
(B) Orthotopic BALB/C nude mice with  1x107 CSC spheroids or control Hep3B cells 
injected into liver of each animal (n=3 in each group). Tumor tissues of BALB/C xenograft 
were further studied for EpCAM expression. (C) Western Blot analysis of two Hep3B 
spheroid tumors and control tumor.  EpCAM expression levels were found to be higher in 





Analysis of Human Specimens Found Significant Higher EpCAM 
Expressions in HCC Tissues:      
 Total protein was extracted from 8 pairs of malignant tissues and adjacent 
benign tissues.  Western Blot analysis was performed to analyze the EpCAM and 
β-catenin expression in these tissues (Figure-14.A & B). Results showed that, in 
4 paired tissues, EpCAM expression was higher in malignant tissue compared to 
the benign adjacent tissue (samples 1, 2, 5, and 6). In 3 paired tissues, EpCAM 
expression was only slightly increased in malignant tissue compared to the 
benign adjacent tissue (samples 3, 4, and 8). However, in one pair (sample 7), 
EpCAM expression remained unchanged. β-catenin expression levels were 
found to be high in 5 paired samples (samples 1, 2, 4, 5, and 6).  However, in 
pair 3, pair 7 and pair 8, β-catenin expression levels were found to be lower in 
malignant tissue compared to benign adjacent tissue. 
 We have also examined 24 pairs of HCC tissues and adjacent benign 
control by IHC (Figure-14.C). Our data showed significant increase in EpCAM 
expression in specimens with HCC (483.75 ± 119.92, p<0.0001) when compared 












Figure 14.  Analysis of Human Specimens. Total proteins were extracted from 8 pairs 
of human HCC specimens (tumor tissue and adjacent benign tissue) and analyzed SDS-
PAGE followed by Western Blot for EpCAM and β-catenin expression.  (A) Western blot; 
(B) densitometry image analysis of EpCAM (left) and β-catenin (right) expression in 
malignant tumor tissue and adjacent benign tissue (n=8). T: tumor tissue; B: benign 
adjacent tissue. Total 24 pairs of HCC specimens were analyzed by IHC staining. (C) Left: 
Representative images of IHC EpCAM staining of human tissue specimens. Right: 
Quantified EpCAM expression (n=24, paired benign AD and HCC specimens). 40X 














Recent studies have shown that many epithelial cancers including 
hepatocellular carcinoma (HCC) arise from small subpopulation of cells called 
cancer stem cells (CSCs) [10, 11, 57].  According to CSC theory, tumors are 
hierarchically organized with heterogeneous populations of cells where a few 
subpopulations called CSCs are poorly differentiated and functionally acquire the 
apex position in the hierarchy of differentiation [13]. These poorly differentiated 
CSCs are believed to be responsible for tumor growth and maintenance of tumor 
mass during carcinogenesis. CSCs acquire this apex role by acquiring self-
renewal capability, where asymmetric divisions maintain CSC populations as well 
as contribute to tumor mass by differentiation [58]. Poorly differentiated CSCs 
also possess spheroid formation capabilities under serum-free conditions where 
most differentiated cells cannot survive. CSCs also possess chemoresistance 
property that results in up-regulation of drug resistant transporters [57, 59]. Much 
of the advanced knowledge on CSCs comes from the studies that have used 
FACS technology to isolate and enrich CSCs from primary HCC tumors, and 
then test their propagation in nude mice [18, 19, 34, 60]. This approach, although 
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proven the most valuable, is cumbersome, time-consuming, expensive, and do 
not readily enable either characterization of CSCs or their functional properties. 
Tumor heterogeneity in primary HCC and variation in HCC patients are key 
reasons for these limitations.  In most laboratory conditions, primary tumor cells 
obtained from patient’s HCC tissue, lose their original phenotype during first few 
passages in culture.  In contrast, cell lines derived from hepatoma normally have 
homogeneous cells and lack heterogeneity observed in clinical tumors. Despite 
these limitations, cell lines can provide valuable tools to study drug development, 
characterization, and to investigate biochemical mechanisms.  
Serum-free conditions enriched in growth factors allow cells to grow in an 
anchorage-independent manner, and is a well-documented standard method for 
maintaining undifferentiated cells [46, 61-63]. Spheroids formed in serum-free 
culture have been suggested to mimic not only phenotype but also genotype of 
the primary tumor than cells in normal culture media [48]. One study disagreed 
with this notion and showed that not all cell lines can enrich CSC-like cells in 
spheroid culture, and each cancer cell line should be evaluated subjectively [64]. 
On the other hand, more and more groups are now testing their hypothesis in 
spheroid culture. A recent study reported that simply generating multicellular 
spheres followed by reversal to adherent cell line can significantly change 
phenotype and can be used as in vitro metastatic model [61]. Altogether, 
spheroid cultures provide a balanced approach to enrich and study CSC-like 
cells present in primary tumors with added advantage of reproducibility and 
validity of findings.   
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In the present study, we successfully identified HCC cells with CSC-like 
properties (derived from hepatoma cell lines) using serum-free culture system.  
Enriched spheroid cells showed self-renewal capability, and serially passed for 
more than 10 generations in serum-free culture. HCC CSC spheroids showed 
resistance to chemotherapeutic drug Doxorubicin, with concomitant up-regulation 
of ABCG2 expression - a multi-drug resistant transporter responsible for efflux of 
drug from the cell [28]. We also studied putative HCC CSC markers by flow-
cytometry and ICC. Our findings suggest that EpCAM+, CD90+, CD44+, and 
CD133+ CSC subpopulations were successfully enriched in spheroids compared 
to control group. We also studied reported functional markers (ALDH activity and 
Hoechst 33342 efflux) and confirmed functionally active CSC-like cells in 
spheroids. For final benchmark confirmation, we injected equal numbers of 
spheroids and control cells into established orthotopic mouse models (C57L/J for 
Hepa1-6, and BALB/C for Hep3B) and showed that enriched CSC spheroids 
possess high tumorigenic property contributing to aggressive tumor growth in 
vivo compared to control cells.  
We have analyzed 24 pairs of human HCC specimens and confirmed 
significant up-regulation of EpCAM in HCC tissues compared to adjacent benign 
liver tissues.  EpCAM is an extensively studied CSC marker in HCC, and 
EpCAM+ cells showed higher tumorigenicity and chemoresistance [18]. 
Yamashita et al. studied and suggested a novel HCC classification with 
prognostic implications based on EpCAM+/AFP+ cells in HCC where higher 
numbers of EpCAM+ HCC cells correlated with worse clinical prognosis [33].  A 
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study by Terris et al. suggested EpCAM as a potential Wnt/β-catenin signaling 
target [32]. Our studies in human specimens in 8 pairs of HCC and adjacent 
benign tissues showed concomitant increase and decrease in EpCAM and β–
catenin levels. Also, 5 out of 8 pairs showed increased expression in both 
EpCAM and β-catenin.   
Accumulated evidence have been established that Wnt/β-catenin pathway 
plays a vital role in not only normal stem-cell biology but also in HCC 
carcinogenesis. We found increased levels of β-catenin in HCC spheroids, both 
in the cytoplasm and the nuclei than in control cells. Also, β-catenin downstream 
gene targets (C-MYC, Cyclin-D1, LEF1) were also upregulated, further 
supporting functional consequences of higher β-catenin levels in CSC spheroids. 
Finally, we also found changes in GSK-3β phosphorylation status where HCC 
CSC spheroids have higher levels of S9-phospho-GSK-3β compared to control. 
This could be a possible mechanism for higher β-catenin levels and its 
downstream effect in HCC spheroids need to be investigated further.    
Chemotherapy plays a significant role in decreasing mortality and 
improving the survival in HCC patients. However, chemoresistance whether 
acquired or inherent, greatly affects disease free survival and early HCC 
recurrence in patients. Mechanisms involved in anticancer chemotherapy are 
multifaceted and largely undefined in HCC. Since chemotherapy resistance is an 
important property of CSCs, characterizing CSCs and establishing an in vitro tool 
to study chemotherapy resistance is of great value in translational research. In 
our present study, enriched HCC spheroids showed phenotypic diversity and 
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significant doxorubicin resistance in all three hepatoma cell lines (Hepa1-6, 
HepG2, and Hep3B).  Also we demonstrated higher ABCG2 expressions in CSC 
spheroids compared to control. Recently, two drug resistance studies in breast 
cancer have identified functional role of β-catenin/ABCG2 signaling [39, 40]. 
Study by Chua et al. suggested ABCG2 as transcriptional target of Wnt/β-catenin 
signaling [45].  All these studies together with our results strongly suggested 
Wnt/β-catenin signaling pathway is implicated in HCC chemoresistance via HCC 
CSCs.  
Summary and Future Directions:   
Our work has successfully identified CSC-like properties in HCC 
spheroids. These CSC spheroids showed resistance to Doxorubicin, first line 
drug to treat HCC in clinics. 24 pairs of human specimens we analyzed have 
shown increased expression of EpCAM, well established HCC CSC marker. 
Expression of EpCAM and ABCG2, multi-drug resistant transporter, have been 
implicated in HCC patients and suggested to be under the regulation of Wnt/β-
catenin signaling. However, exact mechanisms are not clear at this point in time.  
We believe that the chemotherapy resistant properties of HCC tumors could be 
contributed by Wnt/β-catenin signaling mediated CSC activation. For future work, 
we will study the role of Wnt/β-catenin signaling in activation/origin of CSCs in 
HCC and findings will be used to establish clinical correlation(s) in HCC patients. 
Expected clinical correlation(s) with HCC prognosis and chemotherapy 
resistance could help in determining treatment modalities during primary tumor 
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